Posted in | News | Nanobusiness

BASF Introduces New NanoSelect Catalysts for Hydrogenation Reactions in Pharma Applications

BASF Catalysts, the global leader in catalysis, will introduce the first two catalysts from its new NanoSelectTM platform technology, NanoSelect LF 100 and NanoSelect LF 200, for use in fine chemical and pharmaceutical applications at the CPhl Worldwide which starts today.

The two catalysts NanoSelect LF 100 and NanoSelect LF 200 were specifically designed to meet the market requirements of providing a Lead-free replacement for Lindlar catalysts, which have long been used in hydrogenation processes. NanoSelect LF 100 and LF 200 are characterized by supported well-defined, unimodal nano-sized palladium clusters and show similar activity and selectivity as Lindlar catalysts in selective hydrogenation reactions. “BASF NanoSelect LF 100 and LF 200 catalysts are an environmentally-friendly alternative for Lindlar catalysts,” says Dr. Hans Donkervoort, Global Product Technology Manager Specialty and Fine Chemicals Catalysts at BASF’s Catalyst Division. “They additionally offer significant cost savings by having a markedly lower Precious Metal content.”

The Catalysts Division is among a number of BASF businesses presenting their extensive expertise for supporting pharmaceutical industry customers at “CPhI Worldwide,” the “Convention on Pharmaceutical Ingredients and Intermediates” that will take place in Frankfurt, Germany, from September 30 through October 2, 2008.

BASF’s booth 30B04, in Hall 3.0, will bear the motto “Pharma Solutions from BASF.” In addition to catalysts, BASF also presents pharma ingredients and custom synthesis services for better drugs, high-end intermediates for the pharmaceutical industry as well as innovative inorganic specialties.

BASF continually develops new intelligent solutions based on the latest catalyst technologies for its customers. The company delivers these “Enabling Technologies” to the fine chemical, pharmaceutical and agrochemical markets to make its customers more successful in their dynamically changing environments. The portfolio of enabling technologies, including precious metal and base metal hetero- and homogeneous catalysts and metal scavenging materials, is continuously strengthened by focused R&D and licensing of new technologies.

BASF’s Catalysts division is the world’s leading supplier of environmental and process catalysts. The group offers exceptional expertise in the development of technologies that protect the air we breathe, produce the fuels that power our world and ensure efficient production of a wide variety of chemicals, plastics, adsorbents and other products.

For more information, please go to www.catalysts.basf.com.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BASF. (2019, February 15). BASF Introduces New NanoSelect Catalysts for Hydrogenation Reactions in Pharma Applications. AZoNano. Retrieved on November 23, 2024 from https://www.azonano.com/news.aspx?newsID=7888.

  • MLA

    BASF. "BASF Introduces New NanoSelect Catalysts for Hydrogenation Reactions in Pharma Applications". AZoNano. 23 November 2024. <https://www.azonano.com/news.aspx?newsID=7888>.

  • Chicago

    BASF. "BASF Introduces New NanoSelect Catalysts for Hydrogenation Reactions in Pharma Applications". AZoNano. https://www.azonano.com/news.aspx?newsID=7888. (accessed November 23, 2024).

  • Harvard

    BASF. 2019. BASF Introduces New NanoSelect Catalysts for Hydrogenation Reactions in Pharma Applications. AZoNano, viewed 23 November 2024, https://www.azonano.com/news.aspx?newsID=7888.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.